title: Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
abstract: Prostate cancer is a common malignancy that develops by structural mutation(s) and/or other genetic alterations in specific genes.The G to T transversions in codon 12 and C to T transitions in codon 13 of KRAS proto-oncogene are predominant point mutations that occur in about 20% of different cancers in human. In the current study it was aimed to investigate the prevalence and predictive significance of KRAS mutations in patients with prostate carcinomas. In a total of 30 fresh tumoural tissue specimens were investigated in patients with prostate carcinoma. All tumoural specimens were histo-pathologically diagnosed and genotyped for codon 12, 13 KRAS point mutations by reverse hybridisation and direct sequencing methods. KRAS mutations were found in 12 (40%) samples with 29 samples deriving from adenocarcinomas and 1 sample was small cell prostate carcinoma. In 1 (3.44%) sample codon 12 was found to be mutated and in 2 (6.8%) samples codon 13 and in 9 (31%) samples combined codon 12 and 13 were found to be mutated particularly in higher grade of tumoural tissues. Our study, based on representative collection of human prostate tumours, indicates that combined mutations in codons 12 and 13 KRAS are relatively infrequent and most commonly occur in prostate carcinomas.
authors: Department of Medical Genetics, Faculty of Medicine, Canakkale Onsekiz Mart University, 17100 Canakkale, Turkey.
authors: Fatma
authors: F
authors: Silan
authors: Yener
authors: Y
authors: Gultekin
authors: Sinem
authors: S
authors: Atik
authors: Davran
authors: D
authors: Kilinc
authors: Cabir
authors: C
authors: Alan
authors: Fazilet
authors: F
authors: Yildiz
authors: Ahmet
authors: A
authors: Uludag
authors: Ozturk
authors: O
authors: Ozdemir
references: Hematol Oncol Clin North Am. 2010 Oct;24(5):861-83
references: 20816578
references: Prostate. 1997 Jan 1;30(1):53-7
references: 9018336
references: J Clin Oncol. 2009 Mar 1;27(7):1130-6
references: 19124802
references: J Urol. 2002 Feb;167(2 Pt 2):966-73; discussion 973-5
references: 11905926
references: Lung India. 2008 Oct;25(4):148-51
references: 21264081
references: Nature. 1989 Dec 7;342(6250):705-8
references: 2531845
references: Int J Epidemiol. 2011 Apr;40(2):480-7
references: 20959354
references: J Urol. 1994 May;151(5):1283-90
references: 7512659
references: Lancet. 2008 May 17;371(9625):1710-21
references: 18486743
references: Cancer Invest. 1993;11(1):25-32
references: 7678540
references: Environ Health Perspect. 1991 Jun;93:125-31
references: 1685441
references: Cancer Genet Cytogenet. 2010 Apr 1;198(1):35-9
references: 20303012
references: Anticancer Res. 2010 Oct;30(10):4229-35
references: 21036746
references: Ann N Y Acad Sci. 2010 Dec;1214:99-121
references: 20958325
references: Eur Urol. 2011 Jan;59(1):61-71
references: 21056534
references: Int J Cancer. 1994 Jul 15;58(2):174-8
references: 8026877
references: Jpn J Clin Oncol. 2011 Feb;41(2):165-71
references: 20926413
references: Cancer Cell. 2002 Mar;1(2):203-9
references: 12086878
references: Semin Cancer Biol. 2009 Jun;19(3):172-80
references: 19429481
references: Mod Pathol. 2010 Oct;23(10):1325-33
references: 20562851
references: J Cell Biochem. 2010 Dec 1;111(5):1082-6
references: 21053280
references: Am J Pathol. 2010 Dec;177(6):3010-24
references: 20971740
references: Baillieres Clin Gastroenterol. 1990 Mar;4(1):151-69
references: 1976394
references: Zhonghua Wai Ke Za Zhi. 2010 Aug 1;48(15):1166-9
references: 21055012
references: Genes Dev. 2010 Sep 15;24(18):1967-2000
references: 20844012
references: Virchows Arch. 2008 Nov;453(5):417-31
references: 18802721
references: J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43
references: 20724726